<?xml version="1.0" encoding="UTF-8"?>
<p id="par0085">At least one person in the USA who had a high-risk laboratory exposure to Nipah virus has received the experimental neutralizing monoclonal antibody (termed m102.4) against the Nipah viral glycoprotein G, on an emergency use basis (
 <xref rid="bib0020" ref-type="bibr">Broder et al., 2016</xref>). In Australia, an equine vaccine against the closely-related Hendra henipavirus to prevent infection in horses has been licensed since 2015 (
 <xref rid="bib0020" ref-type="bibr">Broder et al., 2016</xref>).
</p>
